Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
264 questions in 10 reviews · Other oral health
current versionsNo studies 45 · 17%Ungraded 127 · 48.1%Very low 24 · 9.1%Low 46 · 17.4%Moderate 13 · 4.9%High 9 · 3.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
GTR rm + CAF vs GTR nrm + CAF Aesthetic condition change related to patient's opinion · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | Aesthetic condition change was not reported for this comparison | 0 studies | No studies |
GTR rm associated with bone substitutes + CAF vs SCTG + CAF Clinical attachment level change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD -0.52 [-1.34, 0.30] | 2 studies | Ungraded |
Pedicled buccal fat pad flap (PBFPF) vs Buccal flap (BF) Successful (complete) closure of oro-antral communication · People of any age with oro-antral communications, fistulae, or both caused by dental procedures · One month after surgery Interventions for treating oro‐antral communications and fistulae due to dental procedures (2018) · Cochrane | RR 1.00 [0.83, 1.20] | 1 study · 20 participants | Very low |
Pedicled buccal fat pad flap (PBFPF) vs Buccal flap (BF) Time required for healing · People of any age with oro-antral communications, fistulae, or both caused by dental procedures Interventions for treating oro‐antral communications and fistulae due to dental procedures (2018) · Cochrane | no estimate extracted | 0 studies | No studies |
ADMG + CAF vs CAF Clinical attachment level change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD 0.51 [-0.25, 1.27] | 2 studies · 50 participants | Low |
XCM + CAF vs CAF Gingival recession depth change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD 0.40 [0.11, 0.68] | 2 studies · 104 participants | Low |
GTR rm + CAF vs GTR nrm + CAF Sites with complete root coverage · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | OR 1.33 [0.46, 3.85] | 2 studies | Ungraded |
EMP + CAF vs SCTG + CAF Clinical attachment change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD -0.25 [-0.69, 0.20] | 2 studies · 62 participants | Low |
XCM + CAF vs CAF Keratinized tissue width change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD 0.44 [0.04, 0.85] | 2 studies · 104 participants | Low |
GTR rm associated with bone substitutes + CAF vs GTR rm + CAF Clinical attachment level change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD 0.76 [-0.01, 1.54] | 2 studies | Ungraded |
ADMG + CAF vs SCTG + CAF Clinical attachment level change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD -0.53 [-1.14, 0.08] | 4 studies · 100 participants | Low |
EMP + CAF vs CAF Clinical attachment level change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD 0.22 [-0.02, 0.45] | 3 studies · 136 participants | Low |
EMP + CAF vs CAF Gingival recession depth change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD 0.07 [-0.25, 0.40] | 3 studies · 136 participants | Low |
EMP + CAF vs SCTG + CAF Occurrence of adverse effects or postoperative complications · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | McGuire 2012: patient-reported discomfort statistically significantly higher for SCTG than EMP + CAF, only at 1 month postoperatively | 1 study | Ungraded |
PRF + CAF vs SCTG + CAF Clinical attachment level change · Adult patients with multiple recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD -0.37 [-0.69, -0.06] | 2 studies | Ungraded |
PRF + CAF vs SCTG + CAF Gingival recession depth change · Adult patients with multiple recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD -0.01 [-0.89, 0.86] | 2 studies | Ungraded |
ADMG + CAF vs SCTG + CAF Sites with complete root coverage · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | OR 0.43 [0.13, 1.37] | 2 studies · 50 participants | Low |
EMP + CAF vs SCTG + CAF Keratinized tissue change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD -1.06 [-1.36, -0.76] | 2 studies · 62 participants | Very low |
GTR rm associated with bone substitutes + CAF vs SCTG + CAF Keratinized tissue width change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD -2.38 [-2.84, -1.92] | 2 studies | Ungraded |
EMP + CAF vs CAF Keratinized tissue width change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD 0.35 [0.13, 0.56] | 3 studies · 136 participants | Low |
GTR rm + CAF vs SCTG + CAF Patients' preference for a specific procedure · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | Wang 2001: participants reported greater overall satisfaction with GTR rm than SCTG (reduced treatment time, no need for a second surgical site) | 1 study | Ungraded |
GTR rm associated with bone substitutes + CAF vs GTR rm + CAF Aesthetic condition change related to patient's opinion · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | Aesthetic condition change was not reported for this comparison | 0 studies | No studies |
Non-surgical technique A vs Non-surgical technique B Outcome NR · People of any age with oro-antral communications, fistulae, or both caused by dental procedures Interventions for treating oro‐antral communications and fistulae due to dental procedures (2018) · Cochrane | no estimate extracted | 0 studies | No studies |
GTR rm associated with bone substitutes + CAF vs SCTG + CAF Aesthetic condition change related to patient's opinion · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | Rosetti 2013: patient satisfaction survey indicated all patients satisfied with aesthetic results of both procedures at 18 months; no significant differences between 18- and 30-month assessments | 1 study | Ungraded |
GTR rm + CAF vs GTR nrm + CAF Occurrence of adverse effects or postoperative complications · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | Roccuzzo 1996: membrane exposure reported between the first and second weeks of healing | 1 study | Ungraded |
ADMG + CAF vs CAF Aesthetic condition change related to patient's opinion · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | Aesthetic condition change related to patient's opinion: Not reported (SoF 2) | 0 studies | No studies |
GTR rm + CAF vs SCTG + CAF Sites with complete root coverage · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | OR 0.61 [0.30, 1.24] | 3 studies · 98 participants | Low |
XCM + CAF vs CAF Clinical attachment level change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD 0.37 [-0.09, 0.83] | 2 studies · 104 participants | Low |
XCM + CAF vs CAF Occurrence of adverse effects or postoperative complications · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | Jepsen 2013: no differences regarding pain and discomfort between XCM + CAF and CAF (for all defects) | 1 study | Ungraded |
GTR rm + CAF vs SCTG + CAF Keratinized tissue change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD -1.77 [-2.66, -0.89] | 3 studies · 98 participants | Very low |
EMP + CAF vs CAF Clinical attachment level change (short and medium term) · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short and medium term (6 to 24 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD 0.35 [0.09, 0.61] | 3 studies | Ungraded |
EMP + CAF vs SCTG + CAF Gingival recession change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm) · Short term (6 to 12 months) Root coverage procedures for treating localised and multiple recession‐type defects (2018) · Cochrane | MD -0.39 [-1.27, 0.48] | 2 studies · 62 participants | Very low |
Systemic interventions (aciclovir, thalidomide, corticosteroids, rebamipide, etanercept, colchicine, interferon-alpha) vs Placebo Safety of the intervention including adverse effects · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | SoF 2 (systemic interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim; the review's wording "topical" is a typo for systemic): "8 placebo-controlled trials evaluated topical… | NR | Ungraded |
Sucralfate suspension (topical) vs Placebo suspension Mean duration of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… · End of treatment Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | MD -1.00 [-5.69, 3.69] | 1 study · 35 participants | Ungraded |
Interferon-alpha (topical lozenges, 1000 IU or 2000 IU) vs Placebo Total ulcer burden · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | Kilic 2009 (interferon-alpha lozenges 1000 IU or 2000 IU vs placebo, 84 patients; high risk of selective reporting): the data presented did not allow analysis; authors reported no statistically significant difference… | 1 study · 84 participants | Ungraded |
Interferon-alpha (topical lozenges) vs Placebo Quality of life · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | Kilic 2009 described the use of a quality of life assessment tool but did not report any quality of life data. | 1 study · 84 participants | Ungraded |
Systemic interventions (aciclovir, thalidomide, corticosteroids, rebamipide, etanercept, colchicine, interferon-alpha) vs Placebo Episode duration associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | SoF 2 (systemic interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim; the review's wording "topical" is a typo for systemic): "8 placebo-controlled trials evaluated topical… | NR | Ungraded |
Triamcinolone acetonide 0.1% ointment (topical) vs Phenytoin syrup mouthwash (30 mg in 5 mL) Positive response (not defined) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… · 7 days Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | RR 1.63 [1.13, 2.34] | 1 study · 60 participants | Ungraded |
Cyclosporin (systemic; 10 mg/kg/day) vs Colchicine (systemic; 1 mg daily) Safety of the intervention including adverse effects · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | Masuda 1989: multiple adverse events in the cyclosporin arm; 3 patients withdrew and 9 had a dose reduction as a result. | 1 study · 92 participants | Ungraded |
Colchicine (systemic; 0.5 mg weight-adjusted daily) vs Placebo Total number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… · 24 months Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | MD 2.30 [-3.42, 8.02] | 1 study · 115 participants | Moderate |
Systemic interventions (aciclovir, thalidomide, corticosteroids, rebamipide, etanercept, colchicine, interferon-alpha) vs Placebo Pain associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | SoF 2 (systemic interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim; the review's wording "topical" is a typo for systemic): "8 placebo-controlled trials evaluated topical… | NR | Ungraded |
Sucralfate suspension (topical) vs Placebo suspension Healing time · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… · End of treatment (3 months) Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | MD -1.09 [-2.61, 0.43] | 1 study · 30 participants | Ungraded |
Sucralfate suspension (topical) vs Placebo suspension Number of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… · End of treatment Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | MD 1.40 [-0.15, 2.95] | 1 study · 35 participants | Ungraded |
Sucralfate suspension (topical) vs Placebo suspension Pain (0-3 scale) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… · End of treatment (3 months) Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | MD -0.38 [-0.87, 0.11] | 1 study · 30 participants | Ungraded |
Aciclovir (systemic; 800 mg 5x/day for 1 week then 400 mg 2x/day for 11 weeks) vs Placebo Frequency of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | Davies 1988 (aciclovir vs placebo, 36 patients, cross-over; high risk of reporting bias; concomitant treatments): data were not presented in a usable format; authors reported no statistically significant difference in… | 1 study · 36 participants | Ungraded |
Interferon-alpha (topical; hydrogel or lozenges) vs Placebo Total number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… · 24 weeks (duration of treatment) Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | MD 1.50 [-10.43, 13.43] | 1 study · 61 participants | Ungraded |
Cyclosporin A in orabase (topical) vs Placebo (orabase) Safety of the intervention including adverse effects · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | Ergun 1997: no adverse effects were seen. | 1 study · 24 participants | Ungraded |
Interferon-alpha (systemic; 6 x 10^6 IU subcutaneously 3x/week for 3 months) vs Placebo (subcutaneous) Duration and pain of oral ulceration · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | Alpsoy 2002 (subcutaneous interferon-alpha 6 x 10^6 IU 3x/week for 3 months vs placebo, 50 patients; high risk of reporting bias): data were not presented in a usable format; authors reported a statistically… | 1 study · 50 participants | Ungraded |
Rebamipide (systemic; 300 mg daily) vs Placebo Global aphthae count and pain score · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | Matsuda 2003 (rebamipide 300 mg daily vs placebo, 35 patients; high risk of reporting bias; concomitant treatments): authors stated that rebamipide improved the global evaluation aphthae count and global evaluation… | 1 study · 35 participants | Ungraded |
Etanercept (systemic; 25 mg subcutaneously twice weekly for 4 weeks) vs Placebo (subcutaneous) Mean number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… · Males only Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane | Melikoglu 2005 (etanercept 25 mg s.c. twice weekly for 4 weeks vs placebo, 40 male patients; high risk of reporting bias): authors reported a statistically significant difference in mean number of oral ulcers with… | 1 study · 40 participants | Ungraded |